Gaxos.ai (NASDAQ:GXAI – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Gaxos.ai and Fulgent Genetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gaxos.ai | 1 | 0 | 0 | 0 | 1.00 |
| Fulgent Genetics | 1 | 2 | 1 | 0 | 2.00 |
Fulgent Genetics has a consensus target price of $27.50, suggesting a potential upside of 28.87%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Gaxos.ai.
Volatility & Risk
Insider and Institutional Ownership
42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Gaxos.ai and Fulgent Genetics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gaxos.ai | $1.93 million | 2.38 | -$3.90 million | ($0.50) | -0.85 |
| Fulgent Genetics | $323.93 million | 1.81 | -$60.51 million | ($2.82) | -7.57 |
Gaxos.ai has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Gaxos.ai, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Gaxos.ai and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gaxos.ai | -64.81% | -38.79% | -36.99% |
| Fulgent Genetics | -26.05% | -4.93% | -4.50% |
Summary
Fulgent Genetics beats Gaxos.ai on 9 of the 13 factors compared between the two stocks.
About Gaxos.ai
Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for Gaxos.ai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gaxos.ai and related companies with MarketBeat.com's FREE daily email newsletter.
